Human CD8 alpha&beta (CD8A&CD8B) Heterodimer Protein, His Tag&Tag Free (MALS verified)
分子別名（Synonym）
CD8 alpha & beta,CD8A & CD8B
表達區(qū)間及表達系統(tǒng)（Source）
Human CD8A&CD8B Heterodimer Protein, His Tag&Tag Free (CDA-H52W5) is expressed from human 293 cells (HEK293). It contains AA Ser 22 - Asp 182 (CD8A) & Leu 22 - Pro 170 (CD8B) (Accession # P01732-1 (CD8A) & P10966-1 (CD8B) ).
Predicted N-terminus: Ser 22 (CD8A) & Leu 22 (CD8B)
蛋白結(jié)構(gòu)（Molecular Characterization）
Human CD8A&CD8B Heterodimer Protein, His Tag&Tag Free, produced by co-expression of CD8 alpha and CD8 beta, has a calculated MW of 19.5 kDa (CD8 alpha) and 22.1 kDa (CD8 beta). Subunit CD8 alpha is fused with an acidic tail at the C-terminus and followed by a polyhistidine tag and subunit CD8 beta contains no tag but a basic tail at the C-terminus. As a result of glycosylation, the heterodimer protein migrates as 30-32 kDa and 32-34 kDa under reducing (R) condition, and 30-33 kDa and 58-70 kDa under non-reducing (NR) condition (SDS-PAGE).
內(nèi)毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
純度（Purity）
>95% as determined by SDS-PAGE.
制劑（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景（Background）
在免疫反應(yīng)中起重要作用的完整膜糖蛋白，在抵抗外部和內(nèi)部攻擊的反應(yīng)中具有多種功能。CD8A在細胞表面與CD8B形成二硫鍵連接的異二聚體。CD8A同二聚體分子還促進活化淋巴細胞的存活和分化為記憶性CD8 T細胞。此外，CD8B在CD8+T細胞的胸腺選擇中起著關(guān)鍵作用。CD8B鏈細胞質(zhì)尾部的棕櫚?；稽c有助于將CD8分配到富含信號蛋白的質(zhì)膜脂筏中。
關(guān)鍵字： CD8A&CD8B;CD8A蛋白;CD8B蛋白;ACRO;百普賽斯;
百普賽斯集團ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團業(yè)務(wù)遍布全球，橫跨亞洲、北美洲、歐洲，在中國、美國、瑞士等12個城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計服務(wù)客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。